Zhao Lu, Mei Qingyun, Yu Yongchao, Wang Na, Zhang Dou, Liao Dongying, Zuo Jinhui, Xie Hongxia, Jia Yingjie, Kong Fanming
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Front Oncol. 2022 May 30;12:894214. doi: 10.3389/fonc.2022.894214. eCollection 2022.
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.
近年来，驱动基因阳性非小细胞肺癌（NSCLC）的治疗取得了巨大进展。RET融合在0.7%至2%的NSCLC中可见，且与较年轻的年龄和从不吸烟的状态相关。2021年NSCLC治疗指南推荐了普拉替尼和塞普替尼用于治疗RET融合的NSCLC。本综述概述了RET融合NSCLC治疗的研究进展，确定了当前面临的挑战，并描述了改善这些患者预后的建议。
